<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658357</url>
  </required_header>
  <id_info>
    <org_study_id>BB-PK-103</org_study_id>
    <nct_id>NCT02658357</nct_id>
  </id_info>
  <brief_title>Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant</brief_title>
  <official_title>Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braeburn Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braeburn Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a 6-month, open-label, multiple center study in approximately 50 stable
      subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety,
      tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation
      of two or three, 300 mg Risperidone Implants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a 6-month, open-label, study in approximately 50 stable subjects diagnosed
      with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and
      pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three,
      300 mg Risperidone Implants.

      Subjects who are diagnosed with schizophrenia or schizoaffective disorder according to DSM-V
      and are stable on a daily 4 mg oral dose of Risperidone for at least 8 weeks will be
      recruited into the study.

      Subjects stable on a 4 mg oral dose of Risperidone will be implanted with two or three, 300
      mg, Risperidone Implants. All implants will be placed in the inner aspect of the upper arm.
      Plasma concentrations of Risperidone and the active moiety will be measured prior to
      placement of the Risperidone Implants, throughout the implantation period, and after
      re-converting to oral Risperidone following the removal of the Risperidone Implants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Active Moiety, 9-hydroxy-risperidone and Risperidone</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Efficacy of a Risperidone Implant as Assessed by the Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizo-affective Disorder</condition>
  <arm_group>
    <arm_group_label>600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two, 300 mg Risperidone Implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three, 300 mg Risperidone Implants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone Implant</intervention_name>
    <arm_group_label>600 mg</arm_group_label>
    <arm_group_label>900 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject (and/or a subject's authorized legal representative) has provided written
             informed consent

          2. Patient meets the following criteria:

               -  Outpatient status

               -  PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20%
                  change from screening, the patients cannot participate in the study.

               -  A score of ≤ 3 on the following PANSS items:

                    -  Conceptual disorganization

                    -  Suspiciousness

                    -  Hallucinatory behavior

                    -  Unusual thought content

          3. Subject is male or female between 18 to 60 years of age

          4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to
             Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria

        Exclusion Criteria:

          1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60
             days prior to admission as determined by the Investigator

          2. Subject has a history of suicide attempt in the last year, or in the opinion of the
             investigator is currently at imminent risk of suicide

          3. Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe
             substance use disorder (except for tobacco use disorder) or has a positive urine drug
             screen for prohibited substances at screening.

          4. Have impaired hepatic (ALT/AST &gt;1.5 times higher than the upper limit of normal) or
             renal function (eGFR&lt;50 mL/min)

          5. Previously defined hypersensitivity to Risperidone

          6. History of neuromalignant syndrome (NMS)

          7. Electroconvulsive therapy within 6 months of admission

          8. Requires current use of agents that are strong inhibitors and inducers of cytochrome
             P450 2D6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Segal Institute for Clinical Research 1201 North 37th Avenue</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 7, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <results_first_submitted>February 6, 2020</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 19, 2020</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT02658357/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>600 mg</title>
          <description>Two, 300 mg Risperidone Implants
Risperidone Implant</description>
        </group>
        <group group_id="P2">
          <title>900 mg</title>
          <description>Three, 300 mg Risperidone Implants
Risperidone Implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
      <group_list>
        <group group_id="B1">
          <title>600 mg</title>
          <description>Two, 300 mg Risperidone Implants
Risperidone Implant</description>
        </group>
        <group group_id="B2">
          <title>900 mg</title>
          <description>Three, 300 mg Risperidone Implants
Risperidone Implant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                </category>
                <category>
                  <title>Asian</title>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                </category>
                <category>
                  <title>Black or African American</title>
                </category>
                <category>
                  <title>White</title>
                </category>
                <category>
                  <title>More than one race</title>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone</title>
        <time_frame>6 months</time_frame>
        <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg</title>
            <description>Two, 300 mg Risperidone Implants
Risperidone Implant</description>
          </group>
          <group group_id="O2">
            <title>900 mg</title>
            <description>Three, 300 mg Risperidone Implants
Risperidone Implant</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone</title>
          <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Active Moiety, 9-hydroxy-risperidone and Risperidone</title>
        <time_frame>6 months</time_frame>
        <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg</title>
            <description>Two, 300 mg Risperidone Implants
Risperidone Implant</description>
          </group>
          <group group_id="O2">
            <title>900 mg</title>
            <description>Three, 300 mg Risperidone Implants
Risperidone Implant</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Active Moiety, 9-hydroxy-risperidone and Risperidone</title>
          <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Efficacy of a Risperidone Implant as Assessed by the Positive and Negative Syndrome Scale (PANSS)</title>
        <time_frame>12 months</time_frame>
        <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg</title>
            <description>Two, 300 mg Risperidone Implants
Risperidone Implant</description>
          </group>
          <group group_id="O2">
            <title>900 mg</title>
            <description>Three, 300 mg Risperidone Implants
Risperidone Implant</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Efficacy of a Risperidone Implant as Assessed by the Positive and Negative Syndrome Scale (PANSS)</title>
          <population>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>600 mg</title>
          <description>Two, 300 mg Risperidone Implants
Risperidone Implant</description>
        </group>
        <group group_id="E2">
          <title>900 mg</title>
          <description>Three, 300 mg Risperidone Implants
Risperidone Implant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The product was sold to another company prior to data analysis. The new company closed before the results were completed, so no results are available for this study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christine Kampf</name_or_title>
      <organization>Braeburn</organization>
      <phone>6104678728</phone>
      <email>ckampf@braeburnrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

